Claims

1. An oligonucleotide consisting of the base sequence of any one of SEQ ID NOs: 1-194.

2. The oligonucleotide of claim 1, wherein said oligonucleotide comprises at least one modified internucleoside linkage.

3. The oligonucleotide of claim 2, wherein said modified internucleoside linkage is selected from the group consisting of phosphorothioate, methylphosphonate, phosphotriester, phosphorodithioate, and phosphoselenate linkages.

4. The oligonucleotide of claim 1, wherein said oligonucleotide comprises at least one modified sugar moiety.

5. The oligonucleotide of claim 4, wherein said modified sugar moiety is a 2'-O methoxyethyl or a 2'-O methyl group.

6. The oligonucleotide of claim 1, wherein said oligonucleotide is a chimeric oligonucleotide.

7. The oligonucleotide of claim 6, wherein said chimeric oligonucleotide comprises DNA residues linked together by phosphorothioate linkages, said DNA residues flanked on each side by at least one 2'-O methoxyethyl RNA residue or 2'-O methyl RNA residue linked together by phosphorothioate linkages.

8. The oligonucleotide of claim 7, wherein said DNA residues are flanked on each side by at least three residues selected from the group consisting of 2'-O methoxyethyl RNA residues and 2'-O methyl RNA residues.

9. The oligonucleotide of claim 1, wherein the three most 5' and the three most 3' bases are RNA residues.

10. A method of treating a patient diagnosed as having cancer, said method comprising administering to said patient an oligonucleotide consisting of the base sequence of any one of SEQ ID NOs: 1-194.

11. The method of claim 10, wherein said oligonucleotide comprises at least one modified internucleoside linkage.

12. The method of claim 11, wherein said modified internucleoside linkage is selected from the group consisting of phosphorothioate, methylphosphonate, phosphotriester, phosphorodithioate, and phosphoselenate linkages.

13. The method of claim 10, wherein said oligonucleotide comprises at least one modified sugar moiety.

14. The method of claim 13, wherein said modified sugar moiety is a 2'-O methoxyethyl or a 2'-O methyl group.

15. The method of claim 10, wherein said oligonucleotide is a chimeric oligonucleotide.

16. The method of claim 15, wherein said chimeric oligonucleotide comprises DNA residues linked together by phosphorothioate linkages, said DNA residues flanked

on each side by at least one 2'-O methoxyethyl RNA residue or 2'-O methyl RNA residue linked together by phosphorothioate linkages.

17. The method of claim 16, wherein said DNA residues are flanked on each side by at least three residues selected from the group consisting of 2'-O methoxyethyl RNA residues and 2'-O methyl RNA residues.

18. The method of claim 10, wherein the three most 5' and the three most 3' bases are RNA residues.